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Abstract
Background: Disability weights represent the relative severity of disease stages to be
incorporated in summary measures of population health. The level of agreement on disability
weights in Western European countries was investigated with different valuation methods.
Methods: Disability weights for fifteen disease stages were elicited empirically in panels of health
care professionals or non-health care professionals with an academic background following a
strictly standardised procedure. Three valuation methods were used: a visual analogue scale (VAS);
the time trade-off technique (TTO); and the person trade-off technique (PTO). Agreement among
England, France, the Netherlands, Spain, and Sweden on the three disability weight sets was
analysed by means of an intraclass correlation coefficient (ICC) in the framework of generalisability
theory. Agreement among the two types of panels was similarly assessed.
Results: A total of 232 participants were included. Similar rankings of disease stages across
countries were found with all valuation methods. The ICC of country agreement on disability
weights ranged from 0.56 [95% CI, 0.52–0.62] with PTO to 0.72 [0.70–0.74] with VAS and 0.72
[0.69–0.75] with TTO. The ICC of agreement between health care professionals and non-health
care professionals ranged from 0.64 [0.58–0.68] with PTO to 0.73 [0.71–0.75] with VAS and 0.74
[0.72–0.77] with TTO.
Conclusions: Overall, the study supports a reasonably high level of agreement on disability
weights in Western European countries with VAS and TTO methods, which focus on individual
preferences, but a lower level of agreement with the PTO method, which focuses more on societal
values in resource allocation.
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Summary measures of population health combine infor-
mation on mortality and non-fatal health outcomes in
order to represent the health of a particular population as
a single measure [1]. They are used traditionally for com-
parative judgements of average levels of population
health between populations and over time. Summary
measures of population health were recently used with an
explicit link to health resource allocation, e.g. disability-
adjusted life expectancies (DALE) computed among other
measures for the evaluation of the performance of health
systems in the World Health Report 2000 [2], or disability-
adjusted life years (DALY) for burden of disease estimates
and cost-effectiveness analyses [3-5].
All summary measures of population health are built on
three critical inputs: mortality by age, sex and condition;
epidemiological data on non-fatal health outcomes by
age, sex and condition; and valuations of health states
(disability weights) that assess the relative severity of a
year lived in a particular condition. Whereas mortality
and epidemiological data may be seen as objective meas-
ures, even if scarcity and heterogeneity of data may com-
promise their accuracy, valuations of health states are
undoubtedly subjective measures.
The lack of a gold standard for health state valuation has
led to the development of various valuation methods [6].
The 1996 Global Burden of Disease study (GBD) repre-
sented a milestone in the development of summary meas-
ures of population health, as it established a single set of
several hundred disability weights relating to 107 condi-
tions using the same valuation method [7,8]. The choice
of the specific values of an international panel of about
ten health experts was supported by high correlations of
their disability weights for 22 hypothetical indicator
health states with those of eight panels from National Bur-
den of Disease teams or World Health Organization
(WHO) workshops on burden of disease methods [9].
Since then the assumption of cross-national agreement on
disability weights has been further supported by studies
using similar valuation protocols [10,11], whereas agree-
ment between different types of informants in health have
shown contradictory results [12-15].
One of the primary objectives of the European Disability
Weights (EDW) project was to assess the cross-national
agreement on valuations of health states when elicited
using different methods [16]. In the EDW study, a visual
analogue scale (VAS) measured the severity of health
states relative to the anchoring endpoints of the scale
(worst and best imaginable health states). The time trade-
off technique (TTO) measured the extent to which
respondents would be willing to give up an amount of life
time to avoid a hypothetical condition and be in full
health, and the person trade-off technique (PTO) elicited
directly the health decision maker's trade-off between
severity of illness, the size of the health gain and the
number of people helped [6]. Hypothetical health states
were valued in panels of two possible informants in
health, i.e. health care professionals and the general pub-
lic with an academic background. We report here on the
agreement of disability weights from five Western Euro-
pean countries (England, France, the Netherlands, Spain,
and Sweden) using VAS, TTO and PTO.
Methods
The valuation of health states in the participating Western
European countries followed a standardised protocol with
back and forth translation from English for all valuation
materials [16]. Key points of the valuation procedure were
fixed to limit construct-irrelevant variance:
1. The scenarios to be valued were presented consistently
in the form of a disease label, a brief clinical description
of the disease stage, and a generic health state profile (EQ-
5D extended with a cognitive dimension) [17-19];
2. Three valuation methods were used: visual analogue
scale (VAS), time trade-off (TTO), and person trade-off
(PTO);
3. A structured protocol which allowed for discussion and
deliberation was followed in all panel sessions;
Panel sessions in each country were led by a trained facil-
itator from that country. Facilitators were trained by the
Dutch group who had previous experience in valuation in
panel sessions [11].
Two sources of variance in the valuation of health states
were retained in our interrater reliability study of each val-
uation method: 1) the country; 2) the type of panel
according to medical background of participants.
Panel participants
At least two panels of health care professionals (almost all
medical doctors) and two panels of 'non-health care pro-
fessionals,' each consisting of around ten participants,
were planned for each country. Incentives to participate
were given to health care professionals (medical doctors
were paid in England and Spain, and received continuing
medical education credits in the Netherlands) whereas the
'non-health care professionals' were recruited generally on
local academic webs (they were also paid a small amount
in England). Panels took place in five European countries:
England, France, the Netherlands, Spain, and Sweden,
between March and September 2000.Page 2 of 11
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A list of diseases accounting for almost 80% of years of life
lost due to premature mortality and 80% of years lived
with disability in the Established Market Economies
Region (including all Western European countries) was
extracted from the Global Burden of Disease study [9].
Thirteen diseases were then selected to cover:
1. The main chapters from the ninth revision of the Inter-
national Classification of Diseases,
2. Different dimensions of disability,
3. Very mild to very severe health states.
External health care professionals and public health
experts participated in both the subdivision of selected
diseases into homogenous disease stages with respect to
functional status, treatment and prognosis, and the elabo-
ration of a brief clinical description for each disease stage
[16].
Fifteen disease stages were selected for the panel valuation
procedure: the stages selected covered the full range of dis-
ease severity, from the common cold to a final year of an
unspecified fatal disease. All selected disease stages were
described on a separate sheet with the name of the dis-
ease, the position of the selected disease stage among the
other stages, a brief clinical description and a health state
profile defined using the EQ-5D descriptive system
extended to include a cognitive dimension, i.e. EQ-5D+C
[17-19]. The EQ-5D+C system has six dimensions (mobil-
ity, self-care, usual activities, pain/discomfort, anxiety/
depression, cognition) each with three possible levels of
severity (no problem, some problems, extreme prob-
lems). Consistency of profiles was checked across disease
stages within diseases and across diseases. Figure 1 shows
an example of a disease stage description.
Valuation methods
Pilot studies conducted in participating countries tested
innovative societal valuation methods [20] after the GBD
societal valuation protocol had been criticized at an early
stage of the project on ethical grounds [21,22]. Agreement
on the valuation protocol was reached by consensus, and
the three valuation methods are described below in the
order of their use in panels. In VAS, all fifteen disease
stages were valued; in PTO and TTO the nine chronic dis-
ease stages were valued.
In the self-administered VAS participants were asked to
consider the consequences of living with the disease stage
for one year. The disease stages were first ranked by
decreasing severity, and then scored on a vertical ther-
mometer graded from 0 (the worst imaginable health
state) to 100 (the best imaginable health state) consider-
ing the consequences of living with the disease stage for
one year. The best and the worst disease stages were scored
first.
In the PTO, panel participants played the role of decision-
makers in their country prioritising between two preven-
tive programmes. Several assumptions about the pro-
grammes were made explicit in the panel sessions:
- Prevention means the reduction of occurrence in two to
four years; programmes are of the same costs and other-
wise equal (e.g. age, sex, socio-economic status of groups);
- Both programmes include people of various ages;
- Loss of production for society and burden on family or
caretakers were to be disregarded in decisions.
The PTO session began with the following example: "Pro-
gramme A prevents the occurrence of a rapidly fatal dis-
ease in 100 people in your country in 2 to 4 years' time.
Example of a disease stage description as presented for valuationFigure 1
Example of a disease stage description as presented 
for valuation. The disease stage description included a dis-
ease label (dementia), the disease stage to be valued (marked 
by the arrow), a textual description (in bold) and a generic 
description of the functional health status (using the EQ-
5D+C descriptive system, which has 3 severity levels per 
attribute; one dot indicates the 'moderate' level).
Dementia
Mild dementia
Moderate dementia
Severe dementia
Patient with mild loss of recent memory and some problems in 
planning and organising daily activities, aware of the deterioration in 
cognitive functioning, capable of living independently
No problems in walking about
No problems with washing or dressing self
• Some problems with performing usual activities (e.g. work, study, 
housework, family of leisure activities)
No pain or discomfort
• Moderately anxious or depressed
• Some problems in cognitive functioning (e.g. memory, learning ability, 
concentration, comprehension)Page 3 of 11
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gramme they will live in normal health for a normal life-
time. Programme B prevents the occurrence of severe
vision disorder in a number of people in your country in
2 to 4 years' time. The identity of these people is
unknown. With the programme they will avoid the state
and live in normal health for a normal life time." Partici-
pants determined the number of people in programme B
at which they were indifferent between the two pro-
grammes with the aid of a visual prop that displayed a
stepwise procedure increasing the numbers in programme
B (100, 200, 1000, 10 000, etc.). Indifference numbers
lower than 100 were also allowed [21]. After the example,
participants had to prioritise between the prevention of a
rapidly fatal disease and quadriplegia, and then between
each of the eight chronic disease stages on the one hand,
and quadriplegia on the other. Quadriplegia was thus
used as an anchoring state, linking the valuation of
chronic states to death. After initial individual valuations,
discussion was structured among panel participants by the
facilitator who ensured that participants understood and
were aware of the implications of their choices. Following
discussion panel members had the opportunity to change
their responses if they so wished.
In TTO, panel participants had to imagine someone like
themselves in full health, and choose between living their
remaining 10 years of life in the chronic disease stage or
less time in full health. The number of years at which the
panel participants were indifferent was found using a
"ping-pong" procedure, but participants were allowed not
to trade-off any years of life [23]. The facilitator again
ensured that panel participants fully understood the task.
Finally, participants had the opportunity to reconsider
their responses after discussion in the panel and were
encouraged to compare individual rankings of all disease
stages for all three valuation methods and make changes
to any responses if they so wished.
Statistical analyses
While TTO and PTO responses yield disability weights for
life years directly, the VAS responses in this study do not,
since in the VAS exercise, states of illness were not valued
relative to the state of being dead. For simplicity of
exposition we refer to all health state values as disability
weights (DWs) in the following. Statistical analyses were
performed on the final figures recorded after panel delib-
erations. Following the GBD study convention, DWs were
valued to unity for death (or the worst imaginable health
state in VAS) and zero for full health (or the best imagina-
ble health state in VAS), and were computed as follows for
the three valuation methods:
VAS: DW = 1-score/100;
TTO: DW = 1-years/10;
PTO: DWquadriplegia = 100/numberquadriplegia,
and DWdisease stage = 100/numberdisease stage * DWquadriplegia
As implied in the last two equations, the PTO used quad-
riplegia rather than death as the anchoring state. In cases
in which the DW exceeded 1 due to the chained procedure
in the PTO (i.e. when participants valued quadriplegia
worse than death), the DW was truncated to 1. The pro-
portion of participants who valued quadriplegia worse
than death was recorded as well as changes in PTO and
TTO numbers after panel discussions and consistency
checks across valuation methods.
Rankings of the disease stages based on mean DW com-
puted from VAS, PTO and TTO were compared across
countries and health care professional status with Spear-
man's rank correlation coefficients. In a random effect
model, variance components of disability weight were
estimated for the random effects identified in this study:
1. Disease stages (n = 15 for VAS and n = 9 for TTO and
PTO),
2. Subjects nested within a type of panel (n = 232),
3. Types of panel (health care or non-health care profes-
sional) nested within country (n = 2),
4. Countries (n = 5),
5. Crossed effects of disease stages and other random
effects.
Maximum likelihood estimates of the variance compo-
nents were used to compute the proportion of total vari-
ance accounted for by each random effect. For our
interrater reliability study, two intraclass correlation coef-
ficients were computed according to generalisability the-
ory, which is a specific application of analysis of variance
[24]. A first intraclass correlation coefficient measured the
agreement between countries on disability weights
deduced from VAS, TTO and PTO:
(σ2disease + σ2subject(panel) + σ2panel(country) + σ2disease*panel)/
(σ2disease + σ2subject(panel) + σ2panel(country) + σ2disease*panel +σ2country + σ2disease*country + σ2residual).
The numerator includes the variance components of all
random effects on disability weights other than country-
related effects and the residual term, which are added in
the denominator. The closer to unity the intraclass corre-
lation coefficient, the better the agreement of countries onPage 4 of 11
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second intraclass correlation coefficient was computed to
measure the agreement between the two types of panel for
all valuation methods. Non-parametric bootstrap resam-
pling techniques were used to compute 95% confidence
intervals [25], since the complex design of our interrater
reliability study did not allow simple computations [26].
One hundred independent random samples were resam-
pled from individual data depending on country and
panel type. Significance was examined at the 5% level. All
analyses were undertaken using SAS version 8.0 (SAS
Institute, Cary NC).
No general statement about the desired level of the relia-
bility coefficient of a test can be made, because the pur-
pose for which the test is used must always be taken into
account [24]. When tests are intended for important deci-
sions at the individual level, e.g. admission for or discon-
tinuation of a clinical treatment, a reliability coefficient
greater than or equal to 0.90 may be considered as
"good." When tests are intended for less important deci-
sions at the individual level, e.g. evaluation of treatment
outcome, a reliability coefficient greater than or equal to
0.80 may be considered as "good." In our particular case,
where valuation methods were intended for research at
the group level, a reliability coefficient greater than or
equal to 0.70 may be considered as "good," between 0.60
and 0.70 as sufficient, and less than 0.60 as insufficient
[27,28].
Results
A total of 232 participants from England, France, the
Netherlands, Spain and Sweden were included in 13 pan-
els of health care professionals and 10 panels of non-
health care professionals. Overall, 60% of subjects were
females, and the mean age was 40.4 years, with a standard
deviation of 15.2. Mean age differed significantly across
countries as shown in Table 1. Health care professionals
included 84% medical doctors. Health care professionals
differed significantly from non-health care professionals
in age (48.9 ± 14.1 vs. 32.4 ± 11.3) and gender (48% vs.
71% female).
At least one disease stage description was questioned in
panels of either non-health care professionals (8 out of
10) or health care professionals (10 among 13). Similar
proportions of panels of non-health care professionals
and health care professionals also reported difficulties
with prognosis of some disease stages in TTO (74%), the
initial example of PTO (35%), and the PTO valuation
method overall (17%). Table 2 shows that discussion in
panel sessions decreased significantly individual PTO
numbers in five out of nine chronic disease stages. Quad-
riplegia, used as the anchoring state in the chained proce-
dure of PTO valuation, was valued less than death by 61
participants with significant differences across countries,
but not according to health care professional status. In
these participants, quadriplegia PTO-DW was truncated to
1.
Tables 3, 4 and 5 show that disease stages were ranked
similarly between countries according to mean DW com-
puted from the three methods. The averages of the ten
Spearman's rank correlation coefficients between
countries in pairwise comparisons were 0.96, 0.93 and
0.96 for VAS, PTO and TTO, respectively, with minimum
values of 0.94 (Spain/Sweden), 0.87 (France/Sweden)
and 0.88 (England/France), respectively. Similar rankings
were found according to health care professional status
with VAS (0.98), PTO (0.96) and TTO (0.95). Independ-
ence of ranks was rejected at p < 0.0001 in all measures.
Table 6 shows that disease stages accounted for more than
60% of total variance of disability weights from VAS and
TTO, whereas this proportion decreased to 36.7% with
disability weights from PTO. The contribution of system-
atic differences between participants in valuation of the
nine disease stages increased substantially from VAS
(5.4%) to TTO (9.8%) and PTO (16.4%).
Country-related effects accounted for 1.9% of total vari-
ance with VAS, increasing to 3% with TTO and 10.8%
with PTO. The agreement between countries fell from
0.72 with VAS and TTO to 0.56 with PTO. Panel type-
related effects accounted for 1.3% of total variance with
Table 1: Description of panel participants by country.
England France Netherlands Spain Sweden p-value*
Number of 
participants
50 46 50 47 39
Age, mean (std) 41.6 (10.6) 44.9 (24.9) 40.0 (11.1) 32.8 (7.3) 43.3 (13.5) 0.002
Sex, % females 54 57 60 68 59 0.69
Healthcare 
professionals, %
58 48 44 51 41 0.52
* Difference in quantitative and binary variables were tested by ANOVA and Chi-square tests, respectively.Page 5 of 11
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between health care professional panels and non-health
care professional panels decreased from 0.73 with VAS
and 0.74 with TTO to 0.64 with PTO.
Discussion
A total of 232 participants from five western European
countries valued disease stages in health care professional
and non-health care professional panels. Overall we
found a very similar ranking of disease stages across coun-
tries irrespective of the valuation method used. This con-
firms previous findings based on the valuation of
seventeen health conditions, either with VAS through
individual interviews of about fifteen key informants in
fourteen countries from different regions [29], or with
PTO in the GBD study and recent refinements [9,10].
Similar rankings of disability weights are not enough,
however, to judge the appropriateness of a universal disa-
bility weight set used at a cardinal level in summary meas-
ures of population health.
We found that intraclass correlation coefficients measur-
ing agreement between countries were good with VAS and
TTO. At first glance, this finding may appear at odds with
cross-national comparisons of disability weights focusing
on disease conditions separately. Other studies eliciting
values for EQ-5D health states with TTO from the general
public in the United Kingdom and Spain [30], or in the
United Kingdom and Japan [31], showed a high positive
correlation of values between countries, but significant
differences in values were found for a number of health
states. Whereas a great variability in the valuation of
health states is observed within countries [32], the previ-
ous approach does not allow one to disentangle system-
atic differences in valuation between subjects and
between countries. As shown within the framework of
generalisability theory, the subject effect accounted for
more variance of disability weights than the country effect
for all valuation methods.
In the case of the PTO method, the intraclass correlation
coefficient measuring agreement between countries was
insufficient. PTO elicited directly health decision-makers'
trade-offs between preventive programmes and attempted
to get societal preferences between disease stages. Whether
respondents actually took a societal view in PTO
questions (as opposed to an individual view in VAS and
TTO) was not confirmed directly, e.g. through follow-up
interviews, and is certainly worthy of further research. The
PTO method demonstrated a dramatic increase in the sys-
tematic effects related to subjects and countries as com-
pared to VAS and TTO. This might be related to different
views regarding equity across European people [33].
We found that the agreement between people of similar
academic background but of different medical back-
ground was good with VAS and TTO, and sufficient with
PTO. This confirms results of an earlier study in the Neth-
Table 2: Person trade-off (PTO) results in stages of elicitation process in panel sessions (n = 229).
Change in PTO numbers (in thousand) in panel 
sessions
Distribution of final PTO numbers (%) Difference in
distribution of final 
PTO numbers across 
countries (Chi-
squared test)
Difference in
distribution of final 
PTO numbers across 
health care 
professional status 
(Chi-squared test)
Disease stages Difference between 
initial PTO and PTO 
after panel discussion
Difference between
PTO after panel 
discussion and final PTO 
(consistency checks)
<100 = 100 >100
Quadriplegia (anchoring 
state)†
44 44 25 17 58 <0.0001 ns
Severe depression 307** -2 14 9 77 <0.0001 ns
Severe asthma 529*** -4 0 0.5 99.5 ns ns
Stroke (moderate 
permanent impairments)
198 0.9 2 3 95 <0.05 ns
Vision disorder (mild/
moderate)
-44 44 1 0.5 98.5 ns ns
Chronic low back pain 436*** 65 0.5 1 98.5 ns ns
Severe stable angina 
(NYHA3)
224* 44 0 1 99 ns ns
Breast cancer (disease-
free stage without 
sequelae)
76 126 0 1 99 ns ns
Uncomplicated diabetes 144* 39 0 0.5 99.5 ns ns
† PTO reference programme was the prevention of 100 rapidly fatal disease cases in quadriplegia, and 100 cases of quadriplegia in other disease 
stages * p < 0.05, ** p < 0.01, *** p < 0.001 in paired t-test.Page 6 of 11
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informants in health, e.g. individuals in health states,
patients' families, health care professionals and the gen-
eral public, showed contradictory results in Western coun-
tries using the TTO method [12-14] or VAS [15]. In the
absence of clear agreement between possible informants
on disability weights, the United States Panel on Cost-
effectiveness in Health and Medicine stated that the gen-
eral public preferences on health conditions should be
used to inform health care resources allocation [34]. Fur-
ther research should assess differences in valuations
between representative samples of the general public and
the more educated and homogeneous groups used in this
study. In particular, academics who volunteered to partic-
ipate in such a time-consuming enterprise may represent
a biased, highly literate sample of the population of the
country. Academics and medical doctors are in many
cases exposed to a similar global intellectual culture,
which might override the national culture in intellectual
matters. This may be especially true in the context of
developing countries where highly educated people may
have values at odds with those of the general public [35].
The design of our valuation methods may limit compari-
son with other studies. Framing and anchoring effects
were likely to have been present with all three valuation
methods. Among other framing effects, VAS scores are
prone to sequencing effects (i.e. the worst and the best dis-
ease stages were scored first in this study), and the range
of health states considered [23]. The anchoring of the TTO
in a ten-year time frame was fixed for all participants to
ensure comparability of results. However, TTO disability
weights for most disease stages decreased with the age of
these relatively young participants, with older people less
willing to give up an amount of life time to avoid a health
condition than younger people (data not shown). This
may have been of particular relevance in the cross-
national comparisons focusing on disease conditions
separately, since age patterns differed between participat-
ing countries.
Table 3: Ranking of fifteen disease stages according to mean visual analogue scale values in 5 Western European countries and by 
professional category (standard deviation in parentheses).
All England France Netherlands Spain Sweden Health care 
professionals
Non-health care 
professionals
Disease stages (n = 230) (n = 49) (n = 46) (n = 50) (n = 46) (n = 39) (n = 111) (n = 119)
Common cold 0.03 (0.04) 0.04 (0.06) 0.03 (0.02) 0.03 (0.04) 0.04 (0.04) 0.03 (0.03) 0.03 (0.04) 0.03 (0.04)
Vision disorder 
(mild/moderate)
0.17 (0.17) 0.17 (0.14) 0.29 (0.29) 0.13 (0.08) 0.15 (0.11) 0.14 (0.08) 0.22 (0.22) 0.13 (0.09)
Breast cancer 
(disease-free 
stage without 
sequelae)
0.32 (0.18) 0.37 (0.22) 0.29 (0.19) 0.27 (0.14) 0.39 (0.15) 0.26 (0.14) 0.33 (0.17) 0.30 (0.18)
Chronic low 
back pain
0.33 (0.18) 0.37 (0.20) 0.34 (0.17) 0.28 (0.15) 0.32 (0.16) 0.36 (0.20) 0.30 (0.17) 0.36 (0.18)
Uncomplicated 
diabetes
0.34 (0.16) 0.40 (0.17) 0.30 (0.14) 0.31 (0.15) 0.31 (0.14) 0.37 (0.16) 0.36 (0.16) 0.31 (0.15)
Mild dementia 0.46 (0.21) 0.50 (0.23) 0.46 (0.23) 0.46 (0.20) 0.47 (0.19) 0.41 (0.21) 0.47 (0.20) 0.45 (0.22)
Severe asthma 0.46 (0.19) 0.53 (0.20) 0.43 (0.23) 0.43 (0.16) 0.43 (0.17) 0.48 (0.15) 0.49 (0.18) 0.43 (0.19)
Colorectal 
cancer 
(diagnosis and 
primary 
therapy)
0.51 (0.20) 0.53 (0.22) 0.48 (0.21) 0.47 (0.14) 0.64 (0.15) 0.41 (0.18) 0.49 (0.18) 0.53 (0.21)
AIDS (minor 
symptoms and 
HAART)
0.55 (0.22) 0.56 (0.21) 0.60 (0.22) 0.43 (0.21) 0.65 (0.21) 0.52 (0.20) 0.56 (0.22) 0.54 (0.22)
Severe stable 
angina (NYHA3)
0.59 (0.16) 0.65 (0.15) 0.58 (0.18) 0.54 (0.13) 0.59 (0.14) 0.56 (0.15) 0.59 (0.15) 0.58 (0.17)
Acute 
myocardial 
infarction
0.59 (0.20) 0.64 (0.22) 0.61 (0.22) 0.49 (0.16) 0.67 (0.16) 0.52 (0.18) 0.57 (0.20) 0.60 (0.20)
Stroke 
(moderate 
permanent 
impairments)
0.68 (0.16) 0.69 (0.17) 0.68 (0.17) 0.64 (0.17) 0.75 (0.13) 0.64 (0.15) 0.66 (0.17) 0.70 (0.15)
Severe 
depression
0.78 (0.17) 0.74 (0.22) 0.77 (0.21) 0.82 (0.12) 0.76 (0.13) 0.83 (0.14) 0.78 (0.18) 0.78 (0.17)
Quadriplegia 0.91 (0.10) 0.89 (0.12) 0.93 (0.07) 0.89 (0.07) 0.94 (0.06) 0.88 (0.13) 0.90 (0.10) 0.91 (0.09)
Final year of 
unspecified fatal 
disease
0.91 (0.10) 0.92 (0.09) 0.96 (0.05) 0.87 (0.11) 0.95 (0.06) 0.87 (0.12) 0.90 (0.11) 0.93 (0.09)
Acquired Immune Deficiency Syndrome (AIDS); Highly Active Anti-Retroviral Therapy (HAART); New-York Heart Association (NYHA)Page 7 of 11
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of rescue" encapsulated by the technique, i.e. valuations
take into account the initial disease severity of the pro-
grammes' recipients in particular in lifesaving pro-
grammes. Quadriplegia as the anchoring state had various
consequences at the country level. Firstly, 43% of
participants thought that the prevention of quadriplegia
should receive a higher or equal priority to that of a life-
saving program. This finding was not related to age of par-
ticipant but differed significantly across countries, from
23% in Sweden to 25% in Spain, 37% in France, 56% in
England, and 64% in the Netherlands. Secondly, 24% and
5% of participants thought that the prevention of severe
depression and stroke, respectively, should receive a
higher or equal priority to that of quadriplegia with signif-
icant variation across countries (from 4% in Spain to 12%
in France, 20% in Sweden, 28% in England, and 50% in
the Netherlands in case of severe depression).
The PTO-DW of disease stages worse than the PTO refer-
ence programme was truncated to 1 to allow face validity
across different valuation metrics. This truncation means
that there was no differentiation between the different
very severe states, and that, as all responses were recoded
as 1, the level of agreement could obviously be higher
than if ranking of these states was also done. In addition,
participants were encouraged to compare their individual
rankings of the nine chronic disease stages for all three
valuation methods at the end of panel sessions. Spear-
man's rank correlations between valuation methods
increased significantly (in paired t-tests) at the individual
level after these "consistency" checks, by 0.013 (±
Table 4: Ranking of nine disease stages according to mean person trade-off values in 5 Western European countries and by professional 
category (standard deviation in parentheses).
All England France Netherlands Spain Sweden Health care 
professionals
Non-health care 
professionals
Disease stages (n = 229) (n = 50) (n = 43) (n = 50) (n = 47) (n = 39) (n = 111) (n = 118)
Vision disorder (mild/
moderate)
0.006 (0.07) 0.001 (0.00) 0.027 (0.16) 0.001 (0.00) 0.001 (0.01) 0.003 (0.01) 0.012 (0.10) 0.001 (0.00)
Chronic low back pain 0.028 (0.12) 0.067 (0.20) 0.025 (0.15) 0.027 (0.08) 0.003 (0.01) 0.013 (0.03) 0.037 (0.17) 0.020 (0.06)
Uncomplicated diabetes 0.042 (0.15) 0.125 (0.28) 0.025 (0.15) 0.023 (0.04) 0.005 (0.02) 0.020 (0.03) 0.065 (0.21) 0.019 (0.06)
Severe asthma 0.054 (0.18) 0.126 (0.27) 0.029 (0.15) 0.067 (0.20) 0.005 (0.02) 0.030 (0.05) 0.069 (0.21) 0.039 (0.13)
Breast cancer (disease-
free stage without 
sequelae)
0.055 (0.20) 0.175 (0.35) 0.028 (0.15) 0.041 (0.15) 0.004 (0.01) 0.007 (0.01) 0.081 (0.25) 0.030 (0.13)
Severe stable angina 
(NYHA3)
0.109 (0.25) 0.286 (0.37) 0.029 (0.15) 0.132 (0.26) 0.027 (0.05) 0.043 (0.09) 0.133 (0.29) 0.087 (0.19)
Stroke (moderate 
permanent 
impairments)
0.171 (0.31) 0.411 (0.43) 0.060 (0.21) 0.199 (0.30) 0.093 (0.22) 0.043 (0.06) 0.216 (0.38) 0.128 (0.22)
Severe depression 0.342 (0.40) 0.534 (0.46) 0.101 (0.26) 0.630 (0.38) 0.112 (0.21) 0.268 (0.28) 0.394 (0.44) 0.292 (0.35)
Quadriplegia 0.648 (0.36) 0.781 (0.31) 0.501 (0.44) 0.827 (0.27) 0.527 (0.33) 0.554 (0.34) 0.636 (0.38) 0.659 (0.34)
New-York Heart Association (NYHA)
Table 5: Ranking of nine disease stages according to mean time trade-off (TTO) values in 5 Western European countries and by 
professional category (standard deviation in parentheses).
All England France Netherlands Spain Sweden Health care 
professionals
Non-health care 
professionals
Disease stages (n = 232) (n = 50) (n = 46) (n = 50) (n = 47) (n = 39) (n = 113) (n = 119)
Vision disorder (mild/moderate) 0.04 (0.10) 0.04 (0.10) 0.09 (0.19) 0.03 (0.05) 0.01 (0.02) 0.01 (0.03) 0.05 (0.13) 0.03 (0.06)
Chronic low back pain 0.11 (0.12) 0.14 (0.14) 0.04 (0.08) 0.15 (0.12) 0.11 (0.10) 0.08 (0.13) 0.09 (0.11) 0.12 (0.13)
Uncomplicated diabetes 0.13 (0.15) 0.11 (0.16) 0.17 (0.17) 0.14 (0.13) 0.12 (0.08) 0.11 (0.19) 0.09 (0.12) 0.17 (0.16)
Severe asthma 0.15 (0.15) 0.18 (0.15) 0.11 (0.14) 0.23 (0.13) 0.12 (0.15) 0.12 (0.13) 0.14 (0.13) 0.17 (0.16)
Breast cancer (disease-free stage 
without sequelae)
0.20 (0.16) 0.17 (0.13) 0.20 (0.22) 0.27 (0.13) 0.21 (0.14) 0.17 (0.18) 0.18 (0.14) 0.22 (0.18)
Severe stable angina (NYHA3) 0.33 (0.20) 0.33 (0.23) 0.26 (0.22) 0.41 (0.15) 0.39 (0.14) 0.24 (0.21) 0.30 (0.19) 0.36 (0.21)
Stroke (moderate permanent 
impairments)
0.42 (0.24) 0.43 (0.23) 0.40 (0.27) 0.50 (0.22) 0.46 (0.21) 0.30 (0.21) 0.40 (0.24) 0.45 (0.23)
Severe depression 0.67 (0.26) 0.55 (0.32) 0.62 (0.28) 0.81 (0.15) 0.73 (0.18) 0.63 (0.26) 0.63 (0.27) 0.71 (0.25)
Quadriplegia 0.75 (0.24) 0.74 (0.26) 0.73 (0.26) 0.82 (0.17) 0.81 (0.20) 0.65 (0.29) 0.75 (0.24) 0.75 (0.24)
New-York Heart Association (NYHA)Page 8 of 11
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between VAS and PTO; and 0.007 (± 0.0038) between
TTO and PTO. This extra consistency between valuation
methods of different perspectives could alternatively con-
tribute to higher levels of agreement across countries and
health care professional status in the case of PTO-DW, or
to lower levels of agreement in the cases of VAS-DW and
TTO-DW.
Another limitation of this study is related to the validity of
our valuation protocol. Despite great care being taken to
ensure the face validity of disease stages, at least one dis-
ease stage was questioned in a majority of panels of both
health care and non-health care professionals. For
instance, discrepancies between the brief clinical descrip-
tion of spinal cord injuries resulting in quadriplegia and
its generic health state profile were often noted. Difficul-
ties were also encountered with TTO and PTO methods in
spite of the deliberative panel process led by a facilitator
and the high level of education of the participants. If we
are to collect values from the general public as recom-
mended, then we need to put more effort into ensuring
that valuation methods are understood as intended by
respondents. Discussion in panel sessions had a consider-
able impact on individual PTO valuations (see Table 2),
and underlines that the collection of societal values at the
individual level without discussion may hamper its face
validity. Although discussion increased the level of agree-
ment on DW computed from PTO in this study,
differences across countries and health care professional
status were still striking.
Conclusions
This study supports a reasonably high level of agreement
on disability weights in Western European countries with
VAS and TTO methods, but a lower level of agreement
with the PTO method. This study showed that even within
a relatively homogenous and wealthy region, and with a
PTO valuation protocol that may inflate the level of agree-
ment across countries, the agreement on disability
weights was insufficient when a societal perspective was
taken into account, i.e. when the summary measure of
population health was considered explicitly within the
context of health care resource allocation. Accordingly,
this study casts some doubts on the generalisability of the
disability weights computed from PTO used in the Global
Burden of Disease study, although PTO protocols dif-
fered. For any valuation method, the level of agreement
on disability weights requires further evidence in larger
and more representative samples of the general public
within and across regions, as defined by countries' loca-
tion and possibly by similarities in mortality patterns and
cost structures.
However, uncertainty surrounding disability weights may
be considered small when compared to the lack of epide-
miological data in many areas of the world to compare
summary measure of population health across countries,
as in the World Health Report 2000 [36]. In the European
Table 6: Variance components analysis and intraclass correlation coefficients of country and panel agreements with three valuation 
methods.
Visual analogue scale (15 disease 
stages)
Visual analogue scale (9 disease 
stages)
Time trade-off
(9 disease stages)
Person trade-off
(9 disease stages)
Random-effects Proportion of total variance
Subject nested within 
panel*
4.3% 5.4% 9.8% 16.4%
Panel nested within 
country
0,0 0,0 0.7% 2.7%
Country 0.7% 0.1% 1.2% 3.9%
Disease 66.5% 65.4% 61.2% 36.7%
Disease effect crossed 
with:
- panel nested within 
country
0.8% 1.3% 0.4% 0.3%
- country 1.9% 1.8% 1.8% 6.9%
Residual 25.8% 26.0% 24.9% 33.2%
Intraclass correlation coefficient of country agreement**
0.72 (0.65–0.77) 0.72 (0.70–0.74) 0.72 (0.69–0.75) 0.56 (0.52–0.62)
Intraclass correlation coefficient of panel agreement**
0.73 (0.67–0.79) 0.73 (0.71–0.75) 0.74 (0.72–0.77) 0.64 (0.58–0.68)
* Two types of panel either with healthcare professionals or not ** 95% bootstrap confidence intervals estimated on 100 independent random 
samples dependend from country and panel type of the 232 individualsPage 9 of 11
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Population Health Metrics 2003, 1 http://www.pophealthmetrics.com/content/1/1/9Disability Weights study, cross-national comparisons of
burden of disease, as measured by disability-adjusted life
years, showed that differences between European coun-
tries for a given valuation method were negligible in com-
parison to differences in epidemiological estimates [16].
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